Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines

Vaccine

Volumn 29, Issue 45, 2011, Pages 7913-7919

  Andrews, Nick J ^a   Walker, Woolf T ^b   Finn, Adam ^e   Heath, Paul T ^c   Collinson, Andrew C ^d   Pollard, Andrew J ^f   Snape, Matthew D ^f   Faust, Saul N ^b   Waight, Pauline A ^a   Hoschler, Katja ^a   Sheasby, Liz ^a   Waddington, Claire ^f   Kerridge, Simon ^f   Chalk, Jeremy ^f   Reiner, Amanda ^f   John, Tessa ^f   Fletcher, Margaret ^e   Allen, Ruth ^e   Fineman, Natalie ^e   Wilkins, Su ^d   Casey, Michelle ^c   Michaelis, Louise ^c   Oeser, Clarissa ^c   Okike, Ifeanyichukwu ^c   Ladhani, Shamez ^a,c   Miller, Elizabeth ^a   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atopy; Fever; Immunogenicity; Pandemic vaccine; Reactogenicity

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ARTICLE; ATOPY; CHILD; DRUG SAFETY; FEMALE; HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION RISK; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; PANDEMIC INFLUENZA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; VIRION;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 80053628262     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.076     Document Type: Article

References (16)

1. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340(May):c2649.
2. Waddington C.S., Andrews N., Hoschler K., Walker W.T., Oeser C., Reiner A., et al. Open-label, randomised, parallel group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technology Assessment 2010, 14:1-130.
3. Hardelid P., Andrews N.J., Hoschler K., Stanford E., Baguelin M., Waight P.A., et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A H1N1 2009. Health Technology Assessment 2010, 14:115-192.
4. Newport M.J., Goetghebuer T., Weiss H.A., Whittle H., Siegrist C.-A., Marchant A. Genetic regulation of immune responses to vaccines in early life. Genes and Immunity 2004, 5:122-129.
5. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serologic study. The Lancet 2010, 375:1100-1108.
6. Blyth C.C., Currie A.J., Wiertsema S.P., Conway N., Kirkham L.A., Fuery A., et al. Trivalent influenza vaccine and febrile adverse events in Australia 2010. Clinical features and potential mechanisms. Vaccine 2011, 29:5107-5113.
7. de Whalley P, Walker W, Snape MD, Oeser C, Casey M, Moulsdale P, et al. Persistence of antibody against A/California/7/2009 (H1N1) virus, and the immunogenicity and reactogenicity of one dose of a non-adjuvanted trivalent seasonal influenza vaccine, in children one year after a two-dose regimen of either an AS03B-adjuvanted or a non-adjuvanted monovalent pandemic influenza vaccine; Health Technology Assessment, in press.
8. Chief Medical Officer's Update, Department of Health (DH). Available from: [accessed 25.07.11]. http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---December/16/CMO-letter-announcing-amendment-of-Pandemrix-license-to-allow-a-one-dose-schedule-in-children-/.
9. Carmona A., Omeñaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28:5837-5844.
10. Andrews N., Waight P., Yung C.F., Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. The Journal of Infectious Diseases 2011, 203:32-39.
11. Nolan T., Richmond P.C., Formica N.T., Höschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26:6383-6391.
12. Roman F., Vaman T., Kafeja F., Hanon E., Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clinical Infectious Diseases 2010, 51:668-677.
13. De St Fazekas S., Webster R.G. Disquisitions on original antigenic sin 1. Evidence in man. The Journal of Experimental Medicine 1966, 124:331-345.
14. Prymula R., Siegrist C.A., Chlibek R., Zemlickova H., Vackova M., Smetana J., et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 374:1339-1350.
15. Southern J., Gelb D., Andrews N., Waight P.A., Morris R., Cartwright K., et al. Reactogenicity of meningococcal C conjugtae vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations. Human Vaccines 2006, 2:237-242.
16. Rowe J., Yercovich S.T., Richmond P., Suriyaarachchi D., Fisher E., Feddema L., et al. TH2-Associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year olds children. Infection and Immunity 2005, 73:8130-8135.